http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 20 Jul 2026 16:01:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26789622.html <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts: </p><p> <b>Canaccord Genuity 46th Annual Growth Conference (Fireside Chat)</b> </p><ul class="bwlistdisc"> <li> Tuesday, August 11, 2026 (12:00 p.m. ET) </li> </ul><p> Webcast link can be found under Investor Relations/Events section of Arcturus’ <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.arcturusrx.com%2Finvestor-calendar&amp;esheet=54573687&amp;newsitemid=20260720082379&amp;lan=en-US&amp;anchor=website&amp;index=1&amp;md5=3716ea82b5e0b0c54bfd2021e78b3c67" shape="rect">website</a>. </p><p> <b>About Arcturus</b> </p><p> Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26789622.html Mon, 20 Jul 2026 16:01:00 -0400 ARCT O.41325150 http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26789622.html <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts: </p><p> <b>Canaccord Genuity 46th Annual Growth Conference (Fireside Chat)</b> </p><ul class="bwlistdisc"> <li> Tuesday, August 11, 2026 (12:00 p.m. ET) </li> </ul><p> Webcast link can be found under Investor Relations/Events section of Arcturus’ <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.arcturusrx.com%2Finvestor-calendar&amp;esheet=54573687&amp;newsitemid=20260720082379&amp;lan=en-US&amp;anchor=website&amp;index=1&amp;md5=3716ea82b5e0b0c54bfd2021e78b3c67" shape="rect">website</a>. </p><p> <b>About Arcturus</b> </p><p> Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26789622.html Mon, 20 Jul 2026 16:01:00 -0400 ARCT O.41325150 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26789622.html <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts: </p><p> <b>Canaccord Genuity 46th Annual Growth Conference (Fireside Chat)</b> </p><ul class="bwlistdisc"> <li> Tuesday, August 11, 2026 (12:00 p.m. ET) </li> </ul><p> Webcast link can be found under Investor Relations/Events section of Arcturus’ <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.arcturusrx.com%2Finvestor-calendar&amp;esheet=54573687&amp;newsitemid=20260720082379&amp;lan=en-US&amp;anchor=website&amp;index=1&amp;md5=3716ea82b5e0b0c54bfd2021e78b3c67" shape="rect">website</a>. </p><p> <b>About Arcturus</b> </p><p> Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26789622.html Mon, 20 Jul 2026 16:01:00 -0400 ARCT O.41325150 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26789622.html <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts: </p><p> <b>Canaccord Genuity 46th Annual Growth Conference (Fireside Chat)</b> </p><ul class="bwlistdisc"> <li> Tuesday, August 11, 2026 (12:00 p.m. ET) </li> </ul><p> Webcast link can be found under Investor Relations/Events section of Arcturus’ <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.arcturusrx.com%2Finvestor-calendar&amp;esheet=54573687&amp;newsitemid=20260720082379&amp;lan=en-US&amp;anchor=website&amp;index=1&amp;md5=3716ea82b5e0b0c54bfd2021e78b3c67" shape="rect">website</a>. </p><p> <b>About Arcturus</b> </p><p> Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26789622.html Mon, 20 Jul 2026 16:01:00 -0400 ARCT O.41325150 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arcturus+Therapeutics+++++For%3A+Jun+26/26723891.html si-local-file:///var/storage/secattach/20260702/26723891.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arcturus+Therapeutics+++++For%3A+Jun+26/26723891.html Thu, 02 Jul 2026 07:06:00 -0400 ARCT O.41325150 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arcturus+Therapeutics+++++For%3A+Jun+26/26723891.html si-local-file:///var/storage/secattach/20260702/26723891.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arcturus+Therapeutics+++++For%3A+Jun+26/26723891.html Thu, 02 Jul 2026 07:06:00 -0400 ARCT O.41325150 http://www.streetinsider.com/Corporate+News/Arcturus+and+Thermo+Fisher+partner+on+cystic+fibrosis+mRNA+therapy/26723845.html <p>Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) has entered into a manufacturing and clinical research collaboration with Thermo Fisher Scientific to support the Phase 3 development and potential commercialization of ARCT-032, an investigational mRNA therapy for cystic fibrosis, according to a press release from the San Diego-based company.</p> <p>Under the agreement, Thermo Fisher will provide Phase 3 manufacturing, clinical research, and related services through its Accelerator™ Drug Development platform. If Phase 2 results are positive, Arcturus expects to conduct its Phase 3 program through Thermo Fisher's PPD™ clinical research business.</p> <p>Subject to regulatory approval of ARCT-032, Thermo Fisher will receive exclusive commercial manufacturing http://www.streetinsider.com/Corporate+News/Arcturus+and+Thermo+Fisher+partner+on+cystic+fibrosis+mRNA+therapy/26723845.html Thu, 02 Jul 2026 07:00:12 -0400 A.50208735 ARCT O.02594693 O.41325150 http://www.streetinsider.com/Corporate+News/Arcturus+and+Thermo+Fisher+partner+on+cystic+fibrosis+mRNA+therapy/26723845.html <p>Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) has entered into a manufacturing and clinical research collaboration with Thermo Fisher Scientific to support the Phase 3 development and potential commercialization of ARCT-032, an investigational mRNA therapy for cystic fibrosis, according to a press release from the San Diego-based company.</p> <p>Under the agreement, Thermo Fisher will provide Phase 3 manufacturing, clinical research, and related services through its Accelerator™ Drug Development platform. If Phase 2 results are positive, Arcturus expects to conduct its Phase 3 program through Thermo Fisher's PPD™ clinical research business.</p> <p>Subject to regulatory approval of ARCT-032, Thermo Fisher will receive exclusive commercial manufacturing http://www.streetinsider.com/Corporate+News/Arcturus+and+Thermo+Fisher+partner+on+cystic+fibrosis+mRNA+therapy/26723845.html Thu, 02 Jul 2026 07:00:12 -0400 A.50208735 ARCT O.02594693 O.41325150 http://www.streetinsider.com/Corporate+News/Arcturus+and+Thermo+Fisher+partner+on+cystic+fibrosis+mRNA+therapy/26723845.html <p>Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) has entered into a manufacturing and clinical research collaboration with Thermo Fisher Scientific to support the Phase 3 development and potential commercialization of ARCT-032, an investigational mRNA therapy for cystic fibrosis, according to a press release from the San Diego-based company.</p> <p>Under the agreement, Thermo Fisher will provide Phase 3 manufacturing, clinical research, and related services through its Accelerator™ Drug Development platform. If Phase 2 results are positive, Arcturus expects to conduct its Phase 3 program through Thermo Fisher's PPD™ clinical research business.</p> <p>Subject to regulatory approval of ARCT-032, Thermo Fisher will receive exclusive commercial manufacturing http://www.streetinsider.com/Corporate+News/Arcturus+and+Thermo+Fisher+partner+on+cystic+fibrosis+mRNA+therapy/26723845.html Thu, 02 Jul 2026 07:00:12 -0400 A.50208735 ARCT O.02594693 O.41325150 http://www.streetinsider.com/Corporate+News/Arcturus+and+Thermo+Fisher+partner+on+cystic+fibrosis+mRNA+therapy/26723845.html <p>Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) has entered into a manufacturing and clinical research collaboration with Thermo Fisher Scientific to support the Phase 3 development and potential commercialization of ARCT-032, an investigational mRNA therapy for cystic fibrosis, according to a press release from the San Diego-based company.</p> <p>Under the agreement, Thermo Fisher will provide Phase 3 manufacturing, clinical research, and related services through its Accelerator™ Drug Development platform. If Phase 2 results are positive, Arcturus expects to conduct its Phase 3 program through Thermo Fisher's PPD™ clinical research business.</p> <p>Subject to regulatory approval of ARCT-032, Thermo Fisher will receive exclusive commercial manufacturing http://www.streetinsider.com/Corporate+News/Arcturus+and+Thermo+Fisher+partner+on+cystic+fibrosis+mRNA+therapy/26723845.html Thu, 02 Jul 2026 07:00:12 -0400 A.50208735 ARCT O.02594693 O.41325150 http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html <p class="bwalignc"> <i>Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus’ investigational mRNA therapy for Cystic Fibrosis. </p><p> The collaboration will leverage Thermo Fisher's Accelerator™ Drug Development solutions, combining manufacturing and clinical research capabilities to support Phase 3 development through potential commercialization. Thermo Fisher http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html Thu, 02 Jul 2026 07:00:00 -0400 A.50208735 ARCT O.02594693 O.41325150 http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html <p class="bwalignc"> <i>Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus’ investigational mRNA therapy for Cystic Fibrosis. </p><p> The collaboration will leverage Thermo Fisher's Accelerator™ Drug Development solutions, combining manufacturing and clinical research capabilities to support Phase 3 development through potential commercialization. Thermo Fisher http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html Thu, 02 Jul 2026 07:00:00 -0400 A.50208735 ARCT O.02594693 O.41325150 http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html <p class="bwalignc"> <i>Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus’ investigational mRNA therapy for Cystic Fibrosis. </p><p> The collaboration will leverage Thermo Fisher's Accelerator™ Drug Development solutions, combining manufacturing and clinical research capabilities to support Phase 3 development through potential commercialization. Thermo Fisher http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html Thu, 02 Jul 2026 07:00:00 -0400 A.50208735 ARCT O.02594693 O.41325150 http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html <p class="bwalignc"> <i>Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus’ investigational mRNA therapy for Cystic Fibrosis. </p><p> The collaboration will leverage Thermo Fisher's Accelerator™ Drug Development solutions, combining manufacturing and clinical research capabilities to support Phase 3 development through potential commercialization. Thermo Fisher http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html Thu, 02 Jul 2026 07:00:00 -0400 A.50208735 ARCT O.02594693 O.41325150 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html <p class="bwalignc"> <i>Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus’ investigational mRNA therapy for Cystic Fibrosis. </p><p> The collaboration will leverage Thermo Fisher's Accelerator™ Drug Development solutions, combining manufacturing and clinical research capabilities to support Phase 3 development through potential commercialization. Thermo Fisher http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html Thu, 02 Jul 2026 07:00:00 -0400 A.50208735 ARCT O.02594693 O.41325150 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html <p class="bwalignc"> <i>Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus’ investigational mRNA therapy for Cystic Fibrosis. </p><p> The collaboration will leverage Thermo Fisher's Accelerator™ Drug Development solutions, combining manufacturing and clinical research capabilities to support Phase 3 development through potential commercialization. Thermo Fisher http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html Thu, 02 Jul 2026 07:00:00 -0400 A.50208735 ARCT O.02594693 O.41325150 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html <p class="bwalignc"> <i>Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus’ investigational mRNA therapy for Cystic Fibrosis. </p><p> The collaboration will leverage Thermo Fisher's Accelerator™ Drug Development solutions, combining manufacturing and clinical research capabilities to support Phase 3 development through potential commercialization. Thermo Fisher http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html Thu, 02 Jul 2026 07:00:00 -0400 A.50208735 ARCT O.02594693 O.41325150 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html <p class="bwalignc"> <i>Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus’ investigational mRNA therapy for Cystic Fibrosis. </p><p> The collaboration will leverage Thermo Fisher's Accelerator™ Drug Development solutions, combining manufacturing and clinical research capabilities to support Phase 3 development through potential commercialization. Thermo Fisher http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html Thu, 02 Jul 2026 07:00:00 -0400 A.50208735 ARCT O.02594693 O.41325150 http://www.streetinsider.com/New+Coverage/Freedom+Broker+Starts+Arcturus+Therapeutics+%28ARCT%29+at+Buy/26723229.html <p>Freedom Broker initiates coverage on Arcturus Therapeutics (NASDAQ: ARCT) with a Buy rating and a price target of $27.00.</p><p>For an analyst ratings summary and ratings history on Arcturus Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=ARCT">click here</a>. For more ratings news on Arcturus Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=ARCT&amp;type=analyst">click here</a>.</p><p>Shares of Arcturus Therapeutics closed at $6.89 yesterday.</p> http://www.streetinsider.com/New+Coverage/Freedom+Broker+Starts+Arcturus+Therapeutics+%28ARCT%29+at+Buy/26723229.html Thu, 02 Jul 2026 05:37:25 -0400 ARCT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcturus+Therapeutics+++++For%3A+Jun+05++Filed+by%3A+BARLOW+JAMES+F/26648391.html si-local-file:///var/storage/secattach/20260615/26648391.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcturus+Therapeutics+++++For%3A+Jun+05++Filed+by%3A+BARLOW+JAMES+F/26648391.html Mon, 15 Jun 2026 17:02:00 -0400 ARCT O.41325150 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcturus+Therapeutics+++++For%3A+Jun+05++Filed+by%3A+BARLOW+JAMES+F/26648391.html si-local-file:///var/storage/secattach/20260615/26648391.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcturus+Therapeutics+++++For%3A+Jun+05++Filed+by%3A+BARLOW+JAMES+F/26648391.html Mon, 15 Jun 2026 17:02:00 -0400 ARCT O.41325150 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcturus+Therapeutics+++++For%3A+Jun+05++Filed+by%3A+FARRELL+PETER+C/26648397.html si-local-file:///var/storage/secattach/20260615/26648397.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcturus+Therapeutics+++++For%3A+Jun+05++Filed+by%3A+FARRELL+PETER+C/26648397.html Mon, 15 Jun 2026 17:02:00 -0400 ARCT O.41325150 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcturus+Therapeutics+++++For%3A+Jun+05++Filed+by%3A+FARRELL+PETER+C/26648397.html si-local-file:///var/storage/secattach/20260615/26648397.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcturus+Therapeutics+++++For%3A+Jun+05++Filed+by%3A+FARRELL+PETER+C/26648397.html Mon, 15 Jun 2026 17:02:00 -0400 ARCT O.41325150 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcturus+Therapeutics+++++For%3A+Jun+05++Filed+by%3A+HOLMES+EDWARD+W/26648407.html si-local-file:///var/storage/secattach/20260615/26648407.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcturus+Therapeutics+++++For%3A+Jun+05++Filed+by%3A+HOLMES+EDWARD+W/26648407.html Mon, 15 Jun 2026 17:02:00 -0400 ARCT O.41325150 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcturus+Therapeutics+++++For%3A+Jun+05++Filed+by%3A+HOLMES+EDWARD+W/26648407.html si-local-file:///var/storage/secattach/20260615/26648407.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcturus+Therapeutics+++++For%3A+Jun+05++Filed+by%3A+HOLMES+EDWARD+W/26648407.html Mon, 15 Jun 2026 17:02:00 -0400 ARCT O.41325150